Phase 3 trials demonstrated ENCELTO significantly slowed macular photoreceptor loss in MacTel patients over 24 months.
If confirmed, Makary would run one of the nation's leading health agencies, overseeing the regulation of food and drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback